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Gastric cancer cells are resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
and the resistance mechanism is not fully understood. In human gastric cancer MGC803 and BGC823
cells, TRAIL induces insulin-like growth factor-1 receptor (IGF-1R) pathway activation. Treatment
with IGF-1R inhibitor OSI-906 or small interfering RNAs against IGF-1R, prevents IGF-1R pathway
activation and increases TRAIL-induced apoptosis. The TRAIL-induced IGF-1R pathway activation
is promoted by IGF-1R translocation into lipid rafts. Moreover, the translocation of IGF-1R into lipid
rafts is regulated by Casitas B-lineage lymphoma b (Cbl-b). Taken together, TRAIL-induced IGF-1R
activation antagonizes TRAIL-induced apoptosis by Cbl-b-regulated distribution of IGF-1R in lipid
rafts.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction that TRAIL-induced phosphorylation of epidermal growth factorMost gastric cancer patients are diagnosed in the advanced
stages of the disease. Curative treatment options are limited and
mortality is high [1]. To increase therapeutic efﬁcacy, some novel
targeted drugs are being clinically tested. As a member of the
tumor necrosis factor (TNF) family, TNF-related apoptosis-inducing
ligand (TRAIL) is particularly attractive for anti-cancer treatment
due to its high speciﬁcity and low toxicity [2]. TRAIL binding of
death receptor 4 (DR4) and death receptor 5 (DR5), and the recruit-
ment of procaspase-8 through Fas-associated death domain
(FADD) for the formation of death-inducing signaling complex
(DISC), contributes to its ability to induce apoptosis [3]. Some
phase II clinical studies have shown that an agonistic antibody spe-
ciﬁc for TRAIL receptors is safe and well tolerated in patients with
advanced colorectal cancer and non-small cell lung cancer [4,5].
However, it has previously been shown that most gastric cancer
cells are insensitive to TRAIL [6,7]. Accordingly, identiﬁcation of
the mechanisms of TRAIL resistance is the key to reversing
resistance.
Of the various mechanisms of TRAIL resistance, studies have
focused on survival pathway activation. Van et al. demonstratedreceptor (EGFR) resulted in TRAIL resistance in colorectal cancer
cells [8]. We recently showed that TRAIL-induced EGFR activation
antagonized TRAIL-induced apoptosis in gastric cancer cells, and
the inhibition of EGFR activation enhanced TRAIL sensitivity [9].
Whether other survival pathways besides the EGFR pathway are
activated to reduce the function of TRAIL is not fully understood.
Recently, using protein chips to screen multiple receptor tyrosine
kinases, we found that TRAIL also induced insulin-like growth fac-
tor-1 receptor (IGF-1R) activation in gastric cancer cells. IGF-1R is
expressed in many tumors, and especially in gastrointestinal can-
cers [10]. Karasic et al. reported that the IGF-1R signaling pathway
is highly active in metastatic melanoma cells, and combinatorial
treatment with TRAIL and cyclolignan picropodophyllin, a speciﬁc
inhibitor of IGF-1R kinase activity, enhanced the apoptotic effects
on melanoma cells [11]. Moreover, the activation of receptor tyro-
sine kinase EGFR was regulated by lipid rafts [9,12]. Lipid rafts
have also been implicated in the regulation of IGF-1-mediated
activation of the PI3K/Akt pathway and survival of mature
oligodendrocytes [13]. Disruption of membrane rafts with
methyl-beta-cyclodextrin results in inhibition of IGF-1-mediated
Akt phosphorylation and altered oligodendrocyte progenitor cell
morphology [13]. Since lipid rafts are essential for IGF-1R signaling
[14], whether TRAIL-induced IGF-1R activation is involved in TRAIL
resistance in gastric cancer cells, and whether TRAIL inﬂuences
IGF-1R activation through the regulation of lipid rafts warrant
further investigation.
3816 L. Xu et al. / FEBS Letters 587 (2013) 3815–3823In this study, we show that TRAIL-induced IGF-1R activation
antagonizes TRAIL-induced apoptosis. Lipid rafts regulate TRAIL
induction of IGF-1R activation by changing IGF-1R distribution.
2. Materials and methods
2.1. Reagents and antibodies
The dual IGF-1R/IR inhibitor OSI-906 was purchased from Sel-
leckBio (USA). The pan caspase inhibitor zVAD and NF-jB inhibitor
PDTC were from Sigma–Aldrich (USA). Recombinant human TRAIL
was purchased from Cytolab/Peprotech Asia (USA). Anti-poly
(ADP-ribose) polymerase (PARP), anti-caspase-3, anti-caspase-8,
anti-IGF-1R, anti-phospho-IGF-1R (Tyr1131), anti-EGFR, anti-phos-
pho-EGFR (Tyr1068), anti-Akt and anti-phospho-Akt (Ser473)
antibodies were obtained from Cell Signaling Technology (USA).
Anti-ERK, anti-p-ERK 1/2 (Thr 202/Tyr 204), anti-caveolin-1,
anti-IjBa and anti-actin antibodies were obtained from Santa Cruz
Biotechnology (USA).
2.2. Cell cultures
Gastric cancer MGC803 and BGC823 cells were obtained from
the Type Culture Collection of the Chinese Academy of Sciences
(China). The cells were cultured in RPMI 1640 medium containing
10% heat-inactivated fetal bovine serum (FBS) at 37 C under an
atmosphere of 95% air and 5% CO2.
2.3. Flow cytometry analysis
Gastric cancer cells were incubated with the indicated concen-
trations of agents for the indicated times. After ﬁxed with ice-cold
70% ethanol overnight, the samples were incubated with 20 lg/ml
RNase A at 37 C and 10 lg/ml propidium iodide (PI) for 30 min in
the dark. Finally, the samples were evaluated by ﬂow cytometry
and the data were analyzed with CellQuest software (Becton Dick-
inson, San Jose, CA, USA).
2.4. Small interfering RNA transfections
IGF-1R small interfering RNA (siRNA) was obtained from Shang-
hai GeneChem Co. Ltd (China). IGF-1R siRNA was synthesized:
50-GCATGGTAGCCGAAGATTT-30 (sense). The cells were transiently
transfected with IGF-1R siRNA using Lipofectamine 2000 reagent
(Invitrogen, USA), according to the manufacturer’s instructions.
2.5. Isolation of lipid rafts
Gastric cancer cells were then solubilized in 150 ll of prechilled
TXNE buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 5 mM EDTA
and 0.1% Triton X-100) containing protease inhibitors (chymosta-
tin, leupeptin, antipain, and pepstatin) for 10 min on ice. Subse-
quently, the cells were scraped off, extracted and moved into
35% Optiprep (Axis-shield, Norway) in polyallomer ultra tubes
(Sorvall Instruments, USA) by adding 210 ll of 60% Optiprep/0.1%
Triton X-100. The cell lysates were covered with 3.5 ml 30% Opti-
prep in TXNE buffer and 300 ll TXNE buffer. After spin in the ultra-
centrifuge (4 h, 200000g, 4 C) (Sorvall/Kendro, USA), six
fractions were collected from the top. The proteins in fractions
1–2 were taken as the lipid raft fractions.
2.6. Western blot analysis
Gastric cancer cells were solubilized in 1% Triton lysis buffer (1%
Triton X-100, 50 mM Tris–Cl pH 7.4, 150 mM NaCl, 10 mM EDTA,100 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 2 lg/ml aprotinin). Cell
lysate proteins were separated by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis and electrophoretically transferred
to a nitrocellulose membrane (Immoblin-P, Millipore, Bedford,
MA, USA). The membranes were blocked with 5% skimmilk in TBST
buffer (10 mM Tris–Cl pH 7.4, 150 mM NaCl, 0.1% Tween 20) at
room temperature for 1 h and incubated overnight at 4 C with
the indicated primary antibodies. After the appropriate secondary
antibodies were added for 30–45 min at room temperature, the
proteins were detected with enhanced chemiluminescence reagent
(SuperSignal Western Pico Chemiluminescent Substrate; Pierce,
USA) and visualized with the Electrophoresis Gel Imaging Analysis
System (DNR Bio-Imaging Systems, Israel).
2.7. Reverse-transcription-polymerase chain reaction (RT-PCR)
Gastric cancer cells pellets were washed twice with ice-cold PBS
and total RNA extracted with the RNeasy mini kit (Qiagen, Carls-
bad, CA, USA) as described by the manufacturer. RT-PCR was per-
formed with primer pairs for IGF-1: forward (50-CA TTG CTC TCA
ACATCTCCC-30) and reverse (50-ACGAACTGAAGAGCATCCAC-30).
PCR conditions were 94 C for 5 min; 33 cycles of 94 C for 30 s,
59 C for 45 s, 72 C for 30 s; one cycle of 72 C for 10 min. RT-
PCR was performed with primer pairs for actin as a control: for-
ward (50-GTGGGGCGCCCCAGGCACCA-30) and reverse (50-CT CC TT
A
ATGTCACGCACGATTTC-30). PCR conditions were 95 C for 5 min;
35 cycles of 95 C for 45 s, 56 C for 45 s, 72 C for 45 s; one cycle
of 72 C for 10 min. The ampliﬁed products were then separated
on 1.5% agarose gels, stained with ethidium bromide and visual-
ized under UV illumination.
2.8. Enzyme-linked immunoassay (ELISA)
IGF-1 secretion in the supernatant of MGC803 cells were mea-
sured using Human IGF-1 ELISA Kit (CUSABIO Life science, China)
following the manufacturer’s instructions. We used the profes-
sional soft ‘‘Curve Expert 1.4’’ to make a standard curve. According
to the ﬁtting curve, enter the standard OD values, get the actual
contents of IGF-1.
2.9. Statistical analysis
Data were conﬁrmed in three independent experiments and
were expressed as the mean ± standard deviation (S.D.). Differ-
ences between groups were compared using Student’s t-test. SPSS
20.0 computer software was used for statistical analysis and
P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. TRAIL induced IGF-1R and downstream Akt and ERK activation in
gastric cancer cells
We previously demonstrated that gastric cancer MGC803,
BGC823 and SGC7901 cells were resistant to TRAIL [15]. To identify
whether TRAIL resistance in gastric cancer cells is associated with
the activation of the IGF-1R signaling pathway, IGF-1R and down-
stream Akt and ERK activation were detected after TRAIL treat-
ment. TRAIL was used at 100 ng/ml in all experiments [6].
Treatment with TRAIL induced the phosphorylation of IGF-1R,
Akt and ERK in a temporal manner. In MGC803 cells, the phosphor-
ylation of IGF-1R, Akt and ERK induced by TRAIL started at 2 h
post-treatment, reached a peak at 16 h, and declined at 24 h. In
BGC823 cells, the phosphorylation of IGF-1R, Akt and ERK gradu-
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gest that TRAIL resistance in gastric cancer cells may result from
the activation of the IGF-1R pathway induced by TRAIL.
3.2. The inhibition of IGF-1R activation increased TRAIL-induced
apoptosis in gastric cancer cells
To determine whether inhibition of IGF-1R would sensitize gas-
tric cancer cells to TRAIL, we investigated the effect of OSI-906, a
tyrosine kinase dual IGF-1R and insulin receptor (IR) inhibitor, on
TRAIL-induced apoptosis in gastric cancer cells. Preincubation with
30 lM OSI-906 for 1 h inhibited the TRAIL-induced phosphoryla-
tion of IGF-1R, Akt and ERK in MGC803 and BGC823 cells
(Fig. 2A). However, the phosphorylation of EGFR induced by TRAIL
was not affected by OSI-906 (Fig. 2A). OSI-906 alone had little effect
on cell apoptosis after treatment for 24 h (Fig. 2B). Compared with
the treatment with TRAIL alone, preincubation with OSI-906 signif-
icantly increased the rate of cell apoptosis induced by TRAIL in
MGC803 and BGC823 cells (20.26 ± 3.79% vs. 5.61 ± 2.56% and
17.85 ± 2.97% vs. 5.92 ± 2.61%, respectively, P < 0.05, Fig. 2B).
Meanwhile, cleavage of caspase-8, caspase-3 and poly (ADP-ribose)
polymerase (PARP) was detected in cells treated with TRAIL and
OSI-906 (Fig. 2C). To further delineate the role of IGF-1R activation
in TRAIL resistance, MGC803 and BGC823 cells were transiently
transfected with IGF-1R siRNA for 48 h. As shown in Fig. 3A, silenc-
ing of IGF-1R attenuated TRAIL-induced IGF-1R, Akt and ERK acti-
vation. IGF-1R siRNA had no signiﬁcant effect on apoptosis
(Fig. 3B). However, preincubation with IGF-1R siRNA for 48 h fol-
lowed by TRAIL treatment for 24 h resulted in a signiﬁcant increase
in apoptosis compared with treatment with TRAIL alone in
MGC803 and BGC823 cells (18.97 ± 4.07% vs. 4.97 ± 1.98% and
17.28 ± 3.87% vs. 5.08 ± 2.17%, respectively, P < 0.05, Fig. 3B). Cas-
pase-3 and caspase-8 activation and PARP cleavage were also de-
tected in MGC803 and BGC823 cells (Fig. 3C). These results
suggest that inhibition of IGF-1R activation sensitizes gastric can-
cer cells to TRAIL-induced apoptosis.
3.3. TRAIL induced IGF-1R activation through IGF-1R translocation into
lipid rafts in gastric cancer cells
To identify whether endogenous IGF-1 expression and secretion
controlled theactivationof IGF-1R,wedetected IGF-1mRNAexpres-
sion and secretion inMGC803 cells after TRAIL treatment. However,
IGF-1mRNAexpressionwasnot obviously affectedafter TRAIL treat-
ment for 2, 6 h (Fig. 4A). Moreover, IGF-1 secretion in the superna-
tant of MGC803 cells was also not changed after TRAIL treatmentFig. 1. TRAIL induced the activation of IGF-1R and Akt/ERK in gastric cancer cells. MGC80
The phosphorylation of IGF-1R, Akt and ERK was analyzed by Western blot.for 2, 6, and 24 h (Fig. 4B). So, TRAIL did not inﬂuence IGF-1 expres-
sion and secretion, which impossibly further regulated activation of
IGF-1R. Our previous study reported that the activation of NF-jB by
TRAIL is responsible for resistance to TRAIL in gastric cancer cells
[16]. To knowwhether TRAIL-mediated NF-jB activation controlled
IGF-1 and IGF-1R expression levels, we tested IGF-1 mRNA and
IGF-1R protein expression after the treatment of TRAIL and PDTC
(a NF-jB inhibitor). As shown in Fig. 4C, TRAIL triggered rapid acti-
vation of NF-jB, as evidenced by the degradation of IjBa at 6 h,
maintained up to 24 h. However, the IGF-1R protein expression lev-
els were not changed. Preincubation with 25 lM PDTC for 1 h par-
tially prevented TRAIL-induced the degradation of IjBa at 6 and
24 h, but IGF-R protein expression was not inﬂuenced. In addition,
IGF-1 mRNA expression levels were not signiﬁcantly affected by
TRAIL, PDTC or the combination of TRAIL and PDTC for 6 h
(Fig. 4D). Thus, TRAIL-mediated NF-jB activation did not regulate
IGF-1 and IGF-1R expression levels in MGC803 cells. We recently
showed that TRAIL could induce EGFR activation through EGFR
translocation into lipid rafts in gastric cancer cells [9]. Since
IGF-1R is also located in lipid rafts [17], we investigated whether
TRAIL-induced IGF-1R activation was associated with lipid rafts.
Membrane lipid rafts were isolated by ultracentrifugation and
located using caveolin-1 (fractions 1 and 2, Fig. 5A). We found that
TRAIL induced IGF-1R translocation into the lipid raft fractions
(1 and 2) in MGC803 and BGC823 cells (Fig. 5A). The percentage of
IGF-1R in lipid rafts was enhanced after TRAIL treatment
(30.83 ± 4.29% vs. 10.26 ± 3.47% and 19.31 ± 4.62% vs. 4.21 ± 1.98%
for MGC803 and BGC823, respectively, P < 0.05, Fig. 5A). To clarify
whether the inhibition of caspase-8 and caspase-3 affect IGF-R pro-
tein trafﬁc in the cell, membrane lipid rafts of MGC803 cells were
isolated after the treatment of TRAIL and zVAD (a pan caspase inhib-
itor). As shown in Fig. 5B, preincubation with 100 lM zVAD for 1 h
prevented TRAIL-induced cleavage of caspase-8 and caspase-3.
However, the distribution of IGF-1R in the lipid raft fractions (1
and 2) was not obviously changed. The percentage of IGF-1R in lipid
rafts was respectively 38.79 ± 5.07% vs. 41.08 ± 3.39% after TRAIL
and the combination of TRAIL and zVAD treatment (P > 0.05). So,
the inhibition of caspase-8 and caspase-3 did not affect IGF-R distri-
bution in lipid rafts. To further identify whether TRAIL induced IGF-
1Ractivationby lipid rafts,membrane lipid raftswere dissociated by
the cholesterol-depleting agent MbCD. Preincubation with 2.5 mg/
ml MbCD for 30 min partially inactivated TRAIL-induced phosphor-
ylationof IGF-1R, Akt andERK inMGC803andBGC823 cells (Fig. 5C).
Thedata indicate that TRAIL induces IGF-1R activationbypromoting
IGF-1R translocation into lipid rafts and the integrity of lipid rafts is
necessary for IGF-1R activation in gastric cancer cells.3 and BGC823 cells were incubated with 100 ng/ml TRAIL for 0.5, 2, 6, 16 and 24 h.
Fig. 2. The inhibition of IGF-1R activation increased TRAIL-induced apoptosis in gastric cancer cells. (A) MGC803 and BGC823 cells were preincubated with 30 lM IGF-1R
inhibitors OSI-906 for 1 h, then treated with 100 ng/ml TRAIL for 16 h. The phosphorylation of IGF-1R, EGFR, Akt and ERK was analyzed by Western blot. (B) MGC803 and
BGC823 cells were incubated with 30 lMOSI-906 for 1 h, then treated with 100 ng/ml TRAIL for 24 h. Cell apoptosis was quantiﬁed with ﬂow cytometry. ⁄Incubated with OSI-
906 and TRAIL vs. with TRAIL alone, P < 0.05. (C) MGC803 and BGC823 cells were treated under similar conditions to those in Fig. 2B. The expression of caspase-3, caspase-8,
and PARP proteins was analyzed by Western blot.
3818 L. Xu et al. / FEBS Letters 587 (2013) 3815–38233.4. Knockdown of Cbl-b further promoted IGF-1R translocation into
lipid rafts and IGF-1R activation in gastric cancer cells
We previously showed that Cbl-b is a negative regulator of lipid
rafts in mast cells [18], and that knockdown of Cbl-b promotedEGFR translocation into lipid rafts and EGFR activation in gastric
cancer cells [9]. To understand the effect of Cbl-b on the distribu-
tion of IGF-1R in lipid rafts, shRNA plasmids targeting Cbl-b were
transfected into MGC803 cells and stable clones were screened in
the presence of G418. The clones with expression levels of Cbl-b
Fig. 3. The inhibition of IGF-1R expression sensitized gastric cancer cells to TRAIL. (A) MGC803 and BGC823 cells were transiently transfected with IGF-1R siRNA for 48 h,
followed by 100 ng/ml TRAIL for 16 h. The phosphorylation of EGFR, Akt and ERK was analyzed by Western blot. (B) MGC803 and BGC823 cells were transiently transfected
with IGF-1R siRNA for 48 h, followed by 100 ng/ml TRAIL for 24 h. Cell apoptosis was quantiﬁed by ﬂow cytometry. ⁄Incubated with TRAIL in IGF-1R siRNA vs. that in non-
silenced siRNA (NS siRNA), P < 0.05. (C) MGC803 and BGC823 cells were treated under similar conditions to those in Fig. 3B. The expression of caspase-3, caspase-8, and PARP
proteins was analyzed by Western blot.
L. Xu et al. / FEBS Letters 587 (2013) 3815–3823 3819less than 10% of the endogenous level were used for subsequent
experiments (Fig. 6A and Fig. 7A). In non-silenced controls, Cbl-b
translocated into the lipid raft fractions (1 and 2) after TRAIL treat-
ment (Fig. 6A). At the same time, TRAIL induced IGF-1R transloca-
tion into the lipid raft fractions (1 and 2, Fig. 6A). The percentage ofIGF-1R in lipid rafts was enhanced after TRAIL treatment
(38.68 ± 5.29% vs. 20.38 ± 3.46%, P < 0.05, Fig. 6A). Importantly,
knockdown of Cbl-b further promoted IGF-1R translocation into
the lipid raft fractions (1 and 2, Fig. 6A). The percentage of
IGF-1R in lipid rafts was further increased after TRAIL treatment
Fig. 4. TRAIL did not inﬂuence IGF-1 expression and secretion, and NF-jB activation induced by TRAIL did not regulate IGF-1 and IGF-1R expression in gastric cancer cells. (A)
MGC803 cells were incubated with 100 ng/ml TRAIL for 2 and 6 h. The expression of mRNA for IGF-1 was analyzed by RT-PCR. Actin was used as an internal control. (B)
MGC803 cells were incubated with 100 ng/ml TRAIL for 2, 6 and 24 h. The secretion of IGF-1 in the supernatant was analyzed by ELISA. The data shown are the means ± S.D.
(ng/ml/106 cells). (C) MGC803 cells were incubated with 100 ng/ml TRAIL for 2, 6 and 24 h. The expression of IjBa and IGFR proteins was analyzed by Western blot. MGC803
cells were incubated with 100 ng/ml TRAIL, 25 lM PDTC or both of them for 6 or 24 h. The expression of IjBa and IGFR proteins was analyzed by Western blot. (D) MGC803
cells were incubated with 100 ng/ml TRAIL, 25 lM PDTC or both of them for 6 h. The expression of mRNA for IGF-1 was analyzed by RT-PCR. Actin was used as an internal
control.
3820 L. Xu et al. / FEBS Letters 587 (2013) 3815–3823(61.06 ± 6.98% vs. 30.95 ± 4.48%, P < 0.05, Fig. 6A). Moreover, en-
hanced phosphorylation of IGF-1R and downstream Akt and ERK
was detected in Cbl-b knockdown clones compared with the
non-silenced control (Fig. 6B). To further increase the sensitivity
of gastric cancer cells to TRAIL, Cbl-b knockdown clones were pre-
incubated with 30 lMOSI-906 for 1 h followed by TRAIL treatment
for 16 h. This led to the partial inhibition of IGF-1R, Akt and ERK
phosphorylation (Fig. 7A). Knockdown of Cbl-b enhanced the sen-
sitivity of gastric cancer cells to TRAIL (21.02 ± 3.71% vs.
5.12 ± 2.41%, P < 0.05, Fig. 7B). In the non-silenced control, preincu-
bation with OSI-906 increased the rate of cell apoptosis induced by
TRAIL compared with the treatment with TRAIL alone
(17.84 ± 3.28% vs. 5.12 ± 2.41%, P < 0.05, Fig. 7B). Interestingly,
incubation with OSI-906 and TRAIL further increased the rate of
cell apoptosis in Cbl-b knockdown clones (37.76 ± 4.86% vs.
21.02 ± 3.71%, P < 0.05, Fig. 7B). Apoptosis induction was further
corroborated by the cleavage of caspase-3, caspase-8 and PARP
(Fig. 7C). These ﬁndings suggest that TRAIL activates IGF-1R path-
way by Cbl-b-regulation of the redistribution of IGF-1R in lipid
rafts, and the inhibition of IGF-1R activation further increases
TRAIL-induced apoptosis, especially in Cbl-b knockdown clones.4. Discussion
As a promising biological factor, TRAIL is a highly selective mol-
ecule which induces apoptosis in malignant cells. However, gastric
cancer cells are relatively resistant to TRAIL. Previous studies of the
mechanisms of TRAIL resistance have largely focused on the dys-
function of TRAIL apoptosis pathway-associated molecules
[19,20]. Recent studies have shown that activation of the survival
pathway is another important factor causing TRAIL resistance. Li
et al. found that the resistance of nasopharyngeal carcinoma cells
to TRAIL was due to the activation of PI3K/Akt signaling pathway
[21]. Furthermore, the inhibition of EGFR activation induced by
TRAIL could reverse TRAIL resistance in gastric cancer and colorec-
tal cancer cells [8,9]. Moreover, IGF-1R, another kind of receptor
tyrosine kinase, activation also protected melanoma cells from
TRAIL-induced apoptosis [11]. In this study, TRAIL induced the acti-
vation of IGF-1R and downstream Akt/ERK in TRAIL-resistant gas-
tric cancer cells. Treatment with IGF-1R inhibitor OSI-906 or
small interfering RNAs against IGF-1R prevented IGF-1R pathway
activation, and thus increased TRAIL-induced apoptosis. Hu et al.
reported that there was a cross-talk paradigm between IGF-1R
Fig. 5. TRAIL activated IGF-1R pathway by promoting IGF-1R translocation into lipid rafts in gastric cancer cells. (A) MGC803 and BGC823 cells were treated with 100 ng/ml
TRAIL for 6 h, then were lysed and fractionated by the ultracentrifuge. Locations of lipid rafts (fractions 1–2) were determined using Caveolin-1. The distribution of IGF-1R
was analyzed by Western blot. ⁄Treated with TRAIL vs. untreated with TRAIL, P < 0.05. (B) MGC803 cells were treated with 100 ng/ml TRAIL, 100 lM zVAD or both of them for
6 h, then were lysed and fractionated by the ultracentrifuge. Locations of lipid rafts (fractions 1–2) were determined using Caveolin-1. The distribution of IGF-1R was analyzed
by Western blot. Treated with TRAIL vs. treated with TRAIL and zVAD, P > 0.05. MGC803 cells were treated with 100 ng/ml TRAIL, 100 lM zVAD or both of them for 24 h, the
expression of caspase-3 and caspase-8 was analyzed by Western blot. (C) MGC803 and BGC823 cells were incubated with 2.5 mg/ml MbCD for 30 min and then treated with
100 ng/ml TRAIL for 16 h. The phosphorylation of EGFR, Akt and ERK was analyzed by Western blot.
L. Xu et al. / FEBS Letters 587 (2013) 3815–3823 3821and EGFR in colon cancer cells [22]. EGFR activation was down-
stream of the IGF-1R/PI3K pathway after the exposure to transfer-
rin and insulin. Moreover, MAPK/ERK activity was a consequence
of EGFR-mediated signaling [22]. To clarify whether IGF-R has animportant role in EGFR pathway, we used OSI-906 prevented the
activation of IGF-1R and downstream Akt/ERK. However, OSI-906
did not inhibit TRAIL-induced EGFR activation. Thus, EGFR was
not downstream of IGFR, but probably functioned as a parallel
Fig. 6. Knockdown of Cbl-b further promoted IGF-1R translocation into lipid rafts
and IGF-1R pathway activation in gastric cancer cells. (A) The cells were treated
with 100 ng/ml TRAIL for 6 h, then were lysed and fractionated by the ultracen-
trifuge. The distribution of Cbl-b and IGF-1R was analyzed byWestern blot. ⁄Treated
with TRAIL vs. untreated with TRAIL respectively in Cbl-b knockdown cells or in
non-silenced controls (NS control), P < 0.05. (B) The cells were treated with 100 ng/
ml TRAIL for 2, 6, 16 and 24 h. The phosphorylation of IGF-1R, Akt and ERK was
analyzed by Western blot.
Fig. 7. The inhibition of IGF-1R activation enhanced TRAIL-induced apoptosis,
especially in Cbl-b knockdown cells. (A) The cells were preincubated with 30 lM
IGF-1R inhibitors OSI-906 for 1 h, then treated with 100 ng/ml TRAIL for 16 h. The
phosphorylation of IGF-1R, Akt and ERK was analyzed by Western blot. (B) The cells
were incubated with 30 lM OSI-906 for 1 h, then treated with 100 ng/ml TRAIL for
24 h. Cell apoptosis was quantiﬁed with ﬂow cytometry. ⁄Incubated with TRAIL in
Cbl-b knockdown cells vs. that in NS control, P < 0.05. ⁄⁄Incubated with OSI-906 and
TRAIL vs. with TRAIL alone respectively in Cbl-b knockdown cells or NS control,
P < 0.05. ⁄⁄⁄Incubated with OSI-906 and TRAIL in Cbl-b knockdown cells vs. that in
NS control, P < 0.05. (C) The cells were treated under similar conditions to those in
Fig. 6B. The expression of caspase-3, caspase-8, and PARP proteins was analyzed by
Western blot.
3822 L. Xu et al. / FEBS Letters 587 (2013) 3815–3823pathway of IGFR in TRAIL-induced apoptosis in gastric cancer cells.
TRAIL-induced IGF-1R activation may be another factor causing
TRAIL resistance in gastric cancer cells.
IGF ligands regulate tumour growth via autocrine, paracrine
and endocrine regulatory mechanism. The most important single
components in this process are IGF-1 as well as IGF-1R [23]. To
identify whether endogenous IGF-1 expression and secretion con-
trol the activation of IGF-1R, we detected IGF-1 mRNA expression
and secretion in MGC803 cells. In the present study, IGF-1 mRNA
expression and IGF-1 secretion in the supernatant of MGC803 cells
was not affected after TRAIL treatment, which impossibly further
control activation of IGF-1R. In addition, our previous study re-
ported that the activation of NF-jB by TRAIL is responsible for
resistance to TRAIL in gastric cancer cells [16]. However, whether
TRAIL-mediated NF-jB activation controlled IGF-1 and IGF-1R
expression levels is not clear. In the present study, TRAIL triggered
rapid activation of NF-jB, as evidenced by the degradation of IjBa.
However, IGF-1 mRNA and IGF-R protein expression were also not
affected by TRAIL and NF-jB inhibitor PDTC. Thus, TRAIL-mediated
NF-jB activation did not regulate IGF-1 and IGF-1R expressionlevels in MGC803 cells. Receptor tyrosine kinase activation is reg-
ulated by many factors. Except for non-receptor tyrosine kinase Src
[24], lipid rafts have been shown to provide a platform for trigger-
ing receptor tyrosine kinase activation, as seen with EGFR [25].
Similar to EGFR, IGF-1R is also a type of transmembrane receptor
protein and located in lipid rafts [26]. Although IGF-1R activation
is known to be involved in TRAIL resistance in melanoma cells
L. Xu et al. / FEBS Letters 587 (2013) 3815–3823 3823[11], how IGF-1R is activated has not been resolved. Here we
showed that TRAIL induces IGF-1R translocation into lipid rafts
accompanied by IGF-1R pathway activation in MGC803 and
BGC823 cells. Although zVAD prevented TRAIL-induced cleavage
of caspase-8 and caspase-3, but IGF-R protein distribution in lipid
rafts was not obviously changed. Furthermore, preincubation with
the cholesterol-depleting agent MbCD partially prevented IGF-1R
pathway activation induced by TRAIL. Thus, TRAIL induces IGF-1R
activation through lipid rafts in gastric cancer cells. In addition,
ubiquitin ligase Cbl-b is a lipid raft negative regulator [27], and
knockdown of Cbl-b signiﬁcantly promoted EGFR translocation
into lipid rafts and subsequent EGFR activation [9]. We demon-
strated that Cbl-b also regulates IGF-1R distribution in lipid rafts.
Knockdown of Cbl-b enhanced IGF-1R translocation into lipid rafts
and IGF-1R activation. Therefore, Cbl-b-regulated IGF-1R distribu-
tion in lipid rafts is probably an important factor for IGF-1R activa-
tion, which results in TRAIL resistance in gastric cancer cells.
In summary, TRAIL-induced IGF-1R activation by Cbl-b-regu-
lated IGF-1R distribution in lipid rafts antagonizes TRAIL-induced
apoptosis. Therefore, inhibition of IGF-1R signal triggered in lipid
rafts is vital for increasing the sensitivity of gastric cancer cells to
TRAIL.
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